Thilo K.
- Country
- Germany
- Department
- DaVita Clinical Research
Research Overview
- Efficacy and Safety of MK-2060 in Preventing Arteriovenous Graft Thrombosis in End-Stage Renal Disease Patients Undergoing Hemodialysis
- Evaluation of XyloCore Efficacy and Safety Compared to Standard Glucose Solutions in Peritoneal Dialysis for End-Stage Kidney Disease Patients
- Evaluation of Sparsentan Versus Irbesartan on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)
Data & Insights
Has run more than one trial at 32 of 327 partner sites.
Specializations
Renal Vascular Disease
The investigator specializes in managing arteriovenous graft complications in hemodialysis patients, with particular focus on thrombosis prevention in end-stage renal disease.
- Vascular Access Management
- Hemodialysis Complications
- Thrombosis Prevention
Advanced therapeutic approaches for maintaining vascular access functionality in dialysis patients.
Dialysis Innovation
Focuses on advancing peritoneal dialysis treatments through novel solution development and evaluation of glucose-sparing alternatives for end-stage kidney disease patients.
- Peritoneal Dialysis Solutions
- Dialysis Efficiency Metrics
- End-Stage Kidney Disease Management
Exploration of innovative dialysis solutions to enhance treatment outcomes.
Glomerular Diseases
Expertise in treating IgA nephropathy and focal segmental glomerulosclerosis, implementing novel therapeutic approaches for progressive kidney diseases.
- Primary IgA Nephropathy
- FSGS Treatment
- Proteinuria Management
Investigation of targeted therapies including complement inhibition and dual-acting compounds.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.